Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer DOI Creative Commons

Kexin Guo,

Sicheng Li, Xinyu Wu

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 449 - 449

Published: March 31, 2025

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and mortality rates, highlighting the urgent need for early diagnosis treatment. However, of PDAC extremely challenging due to atypical symptoms or absence noticeable symptoms. As a result, many patients are diagnosed local metastasis, even who eligible surgical resection have high postoperative recurrence rate. Consequently, chemotherapy remains primary treatment PDAC. unique biological characteristics not only promote tumor progression metastasis but also often lead chemoresistance, significant barrier successful Recently, nanomaterials garnered attention as promising materials diagnosing treating PDAC, showing great potential in cancer therapy, imaging, drug delivery. Novel targeted nanomedicines, which encapsulate drugs gene therapy products, offer advantages overcoming resistance. These nanomedicines provide innovative solutions limitations conventional improve selectivity cells enhance therapeutic outcomes. Current research focused on development advanced such liposomes, nanotubes, polymer-lipid hybrid systems, aimed at making more effective longer lasting. This review provides detailed overview various utilized outlines future directions their key breakthroughs.

Language: Английский

Knowledge Discovery in Datasets of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer DOI Open Access

Mathilde Resell,

Elisabeth Pimpisa Graarud,

Hanne-Line Rabben

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Knowledge discovery in databases (KDD) can contribute to translational research, also known as medicine, by bridging the gap between vitro and vivo studies clinical applications. Here, we propose a 'systems modeling' workflow for KDD. This framework includes data collection of composition model (various research models) processing (proteomics) analytical (bioinformatics, artificial intelligence/machine leaning pattern evaluation), knowledge presentation, feedback loops hypothesis generation validation. We applied this study pancreatic ductal adenocarcinoma (PDAC). Through approach, identified common proteins human PDAC various models (cells, spheroids organoids) (mouse mice). Accordingly, hypothesized potential targets on hub related signaling pathways, specific signature high topological proteins. Thus, suggest that systems modeling be valuable method KDD, facilitating general particular PADA case.

Language: Английский

Citations

0
Utilization of TEP miRNAs in tumor proliferation, diagnostic evaluation, therapeutic intervention, and prognostic assessment DOI
Yuhan Wang, Ling Jiang, Jie Wang

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: March 26, 2025

Language: Английский

Citations

0
Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study DOI Creative Commons

Kankana Bhattacharjee,

Avik Sengupta, Rahul Kumar

et al.

Frontiers in Bioinformatics, Journal Year: 2025, Volume and Issue: 5

Published: March 28, 2025

Pancreatic Ductal Adenocarcinoma (PDAC) poses a significant health threat characterized by poor clinical outcomes, largely attributable to late detection, chemotherapy resistance, and the absence of tailored therapies. Despite progress in surgical, radiation, treatments, 80% PDAC patients do not benefit optimally from systemic therapy, often due asymptomatic presentation or disease regression upon diagnosis. The disease's progression is influenced complex interactions involving immunological, genetic, environmental factors, among others. However, precise molecular mechanisms underlying remain incompletely understood. A major challenge elucidating PDAC's origins lies deciphering genetic variations governing its network. exhibits heterogeneity, manifesting diverse compositions, cellular attributes, behaviors across within tumors. This diversity complicates diagnosis, treatment strategies, prognostication. Identification "Differentially Expressed Genes" (DEGs) between healthy controls vital for addressing these challenges. These DEGs serve as foundation constructing protein interaction network, with their network properties being assessed further insights. Our analysis revealed five key hub genes (KHGs): EGF, SRC, SDC1, ICAM1 CEACAM5. KHGs were predominantly enriched pathways such as: ErbB signaling pathway, Rap1 etc. Acknowledging therapeutic promise biomarker importance KHGs, we have also pinpointed approved medications identified genes. Nevertheless, it crucial conduct experimental validation on confirm effectiveness context. Overall, this study potential implicated PDAC, offering guidance personalized decision-making molecular-targeted therapy patients.

Language: Английский

Citations

0
Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation DOI
Yuchen Jia, Jie Li,

Wentong Mei

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 154, P. 114528 - 114528

Published: March 31, 2025

Language: Английский

Citations

0
Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer DOI Creative Commons

Kexin Guo,

Sicheng Li, Xinyu Wu

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 449 - 449

Published: March 31, 2025

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and mortality rates, highlighting the urgent need for early diagnosis treatment. However, of PDAC extremely challenging due to atypical symptoms or absence noticeable symptoms. As a result, many patients are diagnosed local metastasis, even who eligible surgical resection have high postoperative recurrence rate. Consequently, chemotherapy remains primary treatment PDAC. unique biological characteristics not only promote tumor progression metastasis but also often lead chemoresistance, significant barrier successful Recently, nanomaterials garnered attention as promising materials diagnosing treating PDAC, showing great potential in cancer therapy, imaging, drug delivery. Novel targeted nanomedicines, which encapsulate drugs gene therapy products, offer advantages overcoming resistance. These nanomedicines provide innovative solutions limitations conventional improve selectivity cells enhance therapeutic outcomes. Current research focused on development advanced such liposomes, nanotubes, polymer-lipid hybrid systems, aimed at making more effective longer lasting. This review provides detailed overview various utilized outlines future directions their key breakthroughs.

Language: Английский

Citations

0